Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Development of Proteasome Inhibitors as Therapeutic Drugs.

Journal of clinical & cellular immunology

Pellom ST, Shanker A.
PMID: 23338480
J Clin Cell Immunol. 2012 Mar 15;5. doi: 10.4172/2155-9899.s5-005.

The proteasome is a multi-unit enzyme complex found in the cytoplasm and nucleus of all eukaryotic cells and is responsible for degradation of unneeded or damaged intracellular proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition...

Cite
Pellom ST, Shanker A. Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol. 2012;5doi: 10.4172/2155-9899.s5-005.
Pellom, S. T., & Shanker, A. (2012). Development of Proteasome Inhibitors as Therapeutic Drugs. Journal of clinical & cellular immunology, 5. https://doi.org/10.4172/2155-9899.s5-005
Pellom, Samuel Troy, and Shanker, Anil. "Development of Proteasome Inhibitors as Therapeutic Drugs." Journal of clinical & cellular immunology vol. (2012): 5. doi: https://doi.org/10.4172/2155-9899.s5-005
Pellom ST, Shanker A. Development of Proteasome Inhibitors as Therapeutic Drugs. J Clin Cell Immunol. 2012 Mar 15;5. doi: 10.4172/2155-9899.s5-005. PMID: 23338480; PMCID: PMC3546515.
Copy Download .nbib Format: NLM
Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung.

Genomics data

Qian J, Zou Y, Wang J, Zhang B, Massion PP.
PMID: 26484266
Genom Data. 2015 Jun 14;5:272-4. doi: 10.1016/j.gdata.2015.06.014. eCollection 2015 Sep.

Chromosome 3q26-28 is a critical region of genomic amplification in non-small cell lung cancer (NSCLC), particularly lung squamous cell carcinomas (SCCs). No molecular therapeutic target has shown clinical utility for SCC, in contrast with adenocarcinomas of the lung. To...

Cite
Qian J, Zou Y, Wang J, et al. Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. Genom Data. 2015;5:272-4doi: 10.1016/j.gdata.2015.06.014.
Qian, J., Zou, Y., Wang, J., Zhang, B., & Massion, P. P. (2015). Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. Genomics data, 5272-4. https://doi.org/10.1016/j.gdata.2015.06.014
Qian, Jun, et al. "Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung." Genomics data vol. 5 (2015): 272-4. doi: https://doi.org/10.1016/j.gdata.2015.06.014
Qian J, Zou Y, Wang J, Zhang B, Massion PP. Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung. Genom Data. 2015 Jun 14;5:272-4. doi: 10.1016/j.gdata.2015.06.014. eCollection 2015 Sep. PMID: 26484266; PMCID: PMC4583673.
Copy Download .nbib Format: NLM
MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer.

Proteomics. Clinical applications

Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, Caprioli RM.
PMID: 21136798
Proteomics Clin Appl. 2008 Oct;2(10):1508-17. doi: 10.1002/prca.200800094. Epub 2008 Sep 10.

Protein signals obtained directly from frozen lung tissue sections using MALDI-MS were used to predict nodal involvement and survival in resected non-small cell lung cancer (NSCLC). We have identified a list of these protein signals and further evaluated their...

Cite
Xu BJ, Gonzalez AL, Kikuchi T, et al. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin Appl. 2008;2(10):1508-17doi: 10.1002/prca.200800094.
Xu, B. J., Gonzalez, A. L., Kikuchi, T., Yanagisawa, K., Massion, P. P., Wu, H., Mason, S. E., Olson, S. J., Shyr, Y., Carbone, D. P., & Caprioli, R. M. (2008). MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics. Clinical applications, 2(10), 1508-17. https://doi.org/10.1002/prca.200800094
Xu, Baogang J, et al. "MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer." Proteomics. Clinical applications vol. 2,10 (2008): 1508-17. doi: https://doi.org/10.1002/prca.200800094
Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, Caprioli RM. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin Appl. 2008 Oct;2(10):1508-17. doi: 10.1002/prca.200800094. Epub 2008 Sep 10. PMID: 21136798; PMCID: PMC3728564.
Copy Download .nbib Format: NLM
Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP.
PMID: 30017829
J Thorac Oncol. 2018 Oct;13(10):1519-1529. doi: 10.1016/j.jtho.2018.06.025. Epub 2018 Jul 11.

INTRODUCTION: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who...

Cite
Sharpnack MF, Ranbaduge N, Srivastava A, et al. Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2018;13(10):1519-1529doi: 10.1016/j.jtho.2018.06.025.
Sharpnack, M. F., Ranbaduge, N., Srivastava, A., Cerciello, F., Codreanu, S. G., Liebler, D. C., Mascaux, C., Miles, W. O., Morris, R., McDermott, J. E., Sharpnack, J. L., Amann, J., Maher, C. A., Machiraju, R., Wysocki, V. H., Govindan, R., Mallick, P., Coombes, K. R., Huang, K., & Carbone, D. P. (2018). Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(10), 1519-1529. https://doi.org/10.1016/j.jtho.2018.06.025
Sharpnack, Michael F, et al. "Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 13,10 (2018): 1519-1529. doi: https://doi.org/10.1016/j.jtho.2018.06.025
Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP. Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2018 Oct;13(10):1519-1529. doi: 10.1016/j.jtho.2018.06.025. Epub 2018 Jul 11. PMID: 30017829; PMCID: PMC7135954.
Copy Download .nbib Format: NLM
The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer.

Biological procedures online

Shinohara ET, Hallahan DE, Lu B.
PMID: 15514699
Biol Proced Online. 2004;6:250-256. doi: 10.1251/bpo95. Epub 2004 Oct 25.

Elucidating the mechanism of over and under expression of proteins is critical in developing a better understanding of cancer. Multiple techniques are used to examine differential expression of proteins in cells and assess changes in protein expression in response...

Cite
Shinohara ET, Hallahan DE, Lu B. The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Biol Proced Online. 2004;6:250-256doi: 10.1251/bpo95.
Shinohara, E. T., Hallahan, D. E., & Lu, B. (2004). The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Biological procedures online, 6250-256. https://doi.org/10.1251/bpo95
Shinohara, Eric T, et al. "The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer." Biological procedures online vol. 6 (2004): 250-256. doi: https://doi.org/10.1251/bpo95
Shinohara ET, Hallahan DE, Lu B. The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Biol Proced Online. 2004;6:250-256. doi: 10.1251/bpo95. Epub 2004 Oct 25. PMID: 15514699; PMCID: PMC524213.
Copy Download .nbib Format: NLM
Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates.

Computational statistics & data analysis

Su PF, Li CI, Shyr Y.
PMID: 24567661
Comput Stat Data Anal. 2014 Jun 01;74:39-51. doi: 10.1016/j.csda.2013.12.006.

Sample size determination is essential to planning clinical trials. Jung (2008) established a sample size calculation formula for paired right-censored data based on the logrank test, which has been well-studied for comparing independent survival outcomes. An alternative to rank-based...

Cite
Su PF, Li CI, Shyr Y. Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Comput Stat Data Anal. 2014;74:39-51doi: 10.1016/j.csda.2013.12.006.
Su, P. F., Li, C. I., & Shyr, Y. (2014). Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Computational statistics & data analysis, 7439-51. https://doi.org/10.1016/j.csda.2013.12.006
Su, Pei-Fang, et al. "Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates." Computational statistics & data analysis vol. 74 (2014): 39-51. doi: https://doi.org/10.1016/j.csda.2013.12.006
Su PF, Li CI, Shyr Y. Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates. Comput Stat Data Anal. 2014 Jun 01;74:39-51. doi: 10.1016/j.csda.2013.12.006. PMID: 24567661; PMCID: PMC3931470.
Copy Download .nbib Format: NLM
Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity.

Genome medicine

Liu Q, Su PF, Zhao S, Shyr Y.
PMID: 25648588
Genome Med. 2014 Dec 11;6(12):117. doi: 10.1186/s13073-014-0117-z. eCollection 2014.

BACKGROUND: Comparative analysis of expression profiles between early and late stage cancers can help to understand cancer progression and metastasis mechanisms and to predict the clinical aggressiveness of cancer. The observed stage-dependent expression changes can be explained by genetic...

Cite
Liu Q, Su PF, Zhao S, et al. Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. Genome Med. 2014;6(12):117doi: 10.1186/s13073-014-0117-z.
Liu, Q., Su, P. F., Zhao, S., & Shyr, Y. (2014). Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. Genome medicine, 6(12), 117. https://doi.org/10.1186/s13073-014-0117-z
Liu, Qi, et al. "Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity." Genome medicine vol. 6,12 (2014): 117. doi: https://doi.org/10.1186/s13073-014-0117-z
Liu Q, Su PF, Zhao S, Shyr Y. Transcriptome-wide signatures of tumor stage in kidney renal clear cell carcinoma: connecting copy number variation, methylation and transcription factor activity. Genome Med. 2014 Dec 11;6(12):117. doi: 10.1186/s13073-014-0117-z. eCollection 2014. PMID: 25648588; PMCID: PMC4293006.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries